On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug application (NDA) of tolebrutinib for non-relapsing, secondary progressive ...
Updates in relapsing-remitting MS from ECTRIMS 2025 examine lifestyle interventions, anti-CD20 therapies, efficacy of fenebrutinib, and bone marrow transplantation as an effective long-term treatment.
Additional early research suggested that combining metformin and clemastine may promote remyelination, offering hope for ...
Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis Paris, September 22, 2025. The US Food and Drug Administration (FDA) has extended by three ...
GSK plc announced plans to invest $30 billion in U.S. research and manufacturing over the next five years and entered a $500 ...
Now, by analyzing thousands of proteins found in the blood, scientists at UC San Francisco have created the clearest picture ...
A well-established diabetes drug alleviated brain inflammation in a female mouse model of multiple sclerosis, suggesting the ...
Paris, September 22, 2025. The US Food and Drug Administration (FDA) has extended by three months the target action date of its review of the new drug application (NDA) of tolebrutinib, an oral and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback